Brokerage Downgrades Hit Pharma Stocks: Cipla, Syngene See Significant Falls

• Cipla and Syngene International shares fell on January 27 following brokerage downgrades.
• JPMorgan downgraded Cipla to "Neutral" with a Rs 1,460 target after disappointing Q3 results, citing a 26% drop in US revenue due to Revlimid generic sales decline and supply chain issues.
• Syngene International shares plunged 9% to a four-year low after Jefferies downgraded it to "Underperform" and cut its price target to Rs 480 from Rs 660.
• Syngene's revenue estimate for FY26 was slashed from above 5% to 3-5%, with Jefferies noting missed estimates, destocking challenges, and a lack of a meaningful project pipeline.
• Cipla's long-term pipeline offers promise from FY28, while Syngene faces growth stagnation.

Why It Matters: Brokerage downgrades led to significant stock declines for Cipla and Syngene due to poor results and outlook.